A company presentation will take place during the conference’s Innovation track on Friday, March 28th at 9:00am. NeauxCancer conference’s Innovation track spotlights the most promising emerging ...

MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013.

Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...

Acute GvHD: Since ibrutinib has inhibitory effects on both, BTK and ITK, a preclinical study determined the ability of ibrutinib to target donor-derived T-cells in an aGvHD model. For exclusion of ...

Each year, approximately 375 pediatric patients in the U.S. are diagnosed with SR-aGvHD. The cost of treating a child who dies of SR-aGvHD within 12 months of transplant is approximately US$2.5 ...

Among a group of heavily pretreated aGvHD patients who were not responding to steroid therapies or had become dependent on them, MaaT013 was associated with an OS rate of 54% at six months ...

We recently published a list of 10 Best Australian Stocks to Buy According to Billionaires. In this article, we are going to ...

Investors are piling into Mesoblast shares on Monday. But why? The post Up 810% in a year, the Mesoblast share price is surging again on Monday. Here's why appeared first on The Motley Fool Australia.

FDA approved Ryoncil ® as the first and only therapy for pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory acute graft versus host disease (SR-aGvHD), ...